Compare Mesoblast Limited (MESO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Royal Caribbean Cruises Ltd — how do they compare? Mesoblast Limited trades at $16.96 (market cap $2.21B), while Royal Caribbean Cruises Ltd trades at $309.51 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 37.2× Mesoblast Limited's market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | RCL | |
|---|---|---|
Market Cap | $2.21B | $82.15B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $365.84 |
52-Week Low | $12.88 | $246.71 |
Enterprise Value | $2.21B | $104.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royal Caribbean (RCL) trades at $308, down 3.75% today, as strong earnings growth and bullish technical signals are tempered by geopolitical concerns affecting European demand. The company reported Q2 2026 EPS of $4.21, beating estimates, and raised full-year guidance, with revenue reaching $17.93B in 2025. Technical analysis shows a bullish trend with support at $305 and resistance at $314, while fundamentals highlight robust profitability with a 23.54% net margin and 45.33% ROE.
RCL presents a compelling growth story with record bookings and fleet expansion through 2028, though risks include high debt levels, capital-intensive spending, and geopolitical volatility. Analyst consensus is bullish with a $343 price target, but investors should weigh strong cash flow generation against ongoing investment requirements and market sensitivity to economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
